IRIS
POROTTO, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.145
EU - Europa 983
AS - Asia 359
SA - Sud America 1
Totale 2.488
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.144
IE - Irlanda 543
CN - Cina 170
GB - Regno Unito 154
UA - Ucraina 114
SG - Singapore 97
KR - Corea 90
IT - Italia 68
GR - Grecia 58
DE - Germania 16
FR - Francia 11
RU - Federazione Russa 8
FI - Finlandia 4
BE - Belgio 2
SE - Svezia 2
BR - Brasile 1
CZ - Repubblica Ceca 1
ES - Italia 1
JP - Giappone 1
MV - Maldive 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 2.488
Salva come PNG Salva come JPEG
Città #
Dublin 516
Jacksonville 233
Santa Clara 184
Chandler 96
Seoul 90
New York 88
Princeton 76
Roxbury 76
Medford 63
Singapore 57
Beijing 41
Des Moines 33
Menlo Park 32
Jinan 21
Wilmington 21
Cambridge 18
Nanjing 17
Shenyang 16
Redwood City 14
Cagliari 12
Caserta 10
Norwalk 10
Fairfield 8
Boardman 7
Hebei 7
Mountain View 7
Naples 7
Ningbo 7
Bremen 6
Haikou 6
Hangzhou 6
Redmond 6
Tianjin 6
Zhengzhou 6
Ann Arbor 5
Lanzhou 5
Rome 5
Taiyuan 5
Avellino 4
Changsha 4
Milan 4
Nanchang 4
Taizhou 4
Woodbridge 4
Guangzhou 3
Jiaxing 3
Andover 2
Brussels 2
Helsinki 2
Lappeenranta 2
Nizhniy Novgorod 2
St Petersburg 2
West Jordan 2
Yekaterinburg 2
Ashburn 1
Brno 1
Ercolano 1
Fuzhou 1
Granada 1
Hanover 1
Male 1
Managua 1
Oslo 1
Perm 1
Ravenna 1
Salerno 1
San Mateo 1
São Paulo 1
Tarquinia 1
Tokyo 1
Trento 1
Voronezh 1
Totale 1.887
Salva come PNG Salva come JPEG
Nome #
Human parainfluenza virus evolution during lung infection of immunocompromised humans promotes viral persistence 85
Analysis of a subacute sclerosing panencephalitis (SSPE) Genotype B3 virus from the 2009/10 South African measles epidemic shows hyperfusogenic F proteins contribute to measles virus infection in the brain 55
Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum 52
Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent 50
Electron tomography imaging of surface glycoproteins on human parainfluenza virus 3: association of receptor binding and fusion proteins before receptor engagement 49
Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides 49
Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane 48
Effects of single α-to-β residue replacements on recognition of an extended segment in a viral fusion protein 47
Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia 43
Measles virus bearing MIBE-derived fusion protein is pathogenic after infection via the respiratory route 41
Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue 40
Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus 40
Fatal measles virus infection prevented by brain-penetrant fusion inhibitors 39
Authentic modeling of human respiratory virus infection in human pluripotent stem cell-derived lung organoids 39
Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus 38
A broad-spectrum antiviral targeting entry of enveloped viruses 38
Biophysical properties and antiviral activities of measles fusion protein derived peptide conjugated with 25-hydroxycholesterol 37
Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length 37
A three-dimensional model of human lung development and disease from pluripotent stem cells 37
Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection 36
The pH-sensitive action of cholesterol-conjugated peptide inhibitors of influenza virus 36
Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro 35
A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity 35
Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus 34
Measles fusion machinery is dysregulated in neuropathogenic variants 33
Viral entry properties required for fitness in humans are lost through rapid genomic change during viral isolation 33
A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism 32
Mechanism of interference mediated by human parainfluenza virus type 3 infection 31
A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity 31
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo 31
Features of circulating parainfluenza virus required for growth in human airway 31
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals 31
Molecular determinants of antiviral potency of paramyxovirus entry inhibitors 30
Measles virus fusion machinery activated by sialic acid binding globular domain 30
Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure infection 30
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment 30
Spring-loaded model revisited: Paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein 29
Kinetic dependence of paramyxovirus entry inhibition 29
A rapid high-throughput assay for the identification of neutralizing antibodies and antiviral molecules against SARS-CoV-2 virus 29
Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo 28
Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion 28
Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein 28
In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence 28
Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection 28
Identification of a region in the stalk domain of the Nipah virus receptor binding protein that is critical for fusion activation 27
Negative staining of proteins in polyacrylamide gels with methyl trichloroacetate 27
Inhibition of Hendra virus fusion 27
Paramyxovirus receptor-binding molecules: Engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site 27
Human parainfluenza virus type 3 HN-receptor interaction: Effect of 4-guanidino-neu5Ac2en on a neuraminidase-deficient variant 27
Human parainfluenza virus infection of the airway epithelium: Viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity 27
Mechanism of fusion triggering by human parainfluenza virus type III: Communication between viral glycoproteins during entry 27
Fusion inhibitory lipopeptides engineered for prophylaxis of nipah virus in primates 27
Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance 26
Regulation of paramyxovirus fusion activation, the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state 26
Modulation of Oncogenic DBL Activity by Phosphoinositol Phosphate Binding to Pleckstrin Homology Domain 26
Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II 26
Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy 26
Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery 26
Viral entry inhibitors targeted to the membrane site of action 26
Single-chain variable fragment antibody constructs neutralize measles virus infection in vitro and in vivo 26
Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides 25
Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir) 25
Unity in diversity: shared mechanism of entry among paramyxoviruses 25
The second receptor binding site of the globular head of the newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion 25
Structure-Stability-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Derivatized Peptide Nanoparticles 25
Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism 25
Inhibition of parainfluenza virus type 3 and newcastle disease virus hemagglutinin-neuraminidase receptor binding: Effect of receptor avidity and steric hindrance at the inhibitor binding sites 24
Inhibition of Nipah Virus Infection In Vivo: Targeting an early stage of paramyxovirus fusion activation during viral entry 24
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets 24
The in vitro multilineage differentiation and maturation of lung and airway cells from human pluripotent stem cell-derived lung progenitors in 3D 24
Design and evaluation of neutralizing and fusion inhibitory peptides to Crimean-Congo hemorrhagic fever virus 21
Hijacking the fusion complex of human parainfluenza virus as an antiviral strategy 20
Human parainfluenza virus fusion complex glycoproteins imaged in action on authentic viral surfaces 20
Molecular Features of the Measles Virus Viral Fusion Complex That Favor Infection and Spread in the Brain 20
Inhibition of Measles Viral Fusion Is Enhanced by Targeting Multiple Domains of the Fusion Protein 20
Engineering Protease-Resistant Peptides to Inhibit Human Parainfluenza Viral Respiratory Infection 19
Structure-Guided Improvement of a Dual HPIV3/RSV Fusion Inhibitor 18
Inhibition of coronavirus entry in vitro and ex vivo by a lipid-conjugated peptide derived from the sars-cov-2 spike glycoprotein hrc domain 17
In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age 17
Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds 15
Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets 13
Intermediates in SARS-CoV-2 spike-mediated cell entry 13
Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern 13
Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection 12
Absence of COVID-19-associated changes in plasma coagulation proteins and pulmonary thrombosis in the ferret model 11
Early Permissiveness of Central Nervous System Cells to Measles Virus Infection Is Determined by Hyperfusogenicity and Interferon Pressure 9
Subnanometer structure of an enveloped virus fusion complex on viral surface reveals new entry mechanisms 8
SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C compared to COVID-19 7
Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments 6
Host Cell Membrane Capture by the SARS-CoV-2 Spike Protein Fusion Intermediate 5
A neutralizing antibody prevents postfusion transition of measles virus fusion protein 5
Antiviral activity of nitazoxanide against Morbillivirus infections 3
Totale 2.602
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.310
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.310
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020162 0 0 0 0 57 4 61 0 0 17 23 0
2020/2021326 9 0 5 18 110 4 62 1 17 37 63 0
2021/2022461 6 1 5 66 159 4 5 11 14 1 33 156
2022/2023673 80 1 0 7 57 36 0 33 426 3 14 16
2023/2024350 25 5 10 4 142 64 1 3 1 2 14 79
2024/2025325 23 100 4 10 188 0 0 0 0 0 0 0
Totale 2.602